• Explore /
  • Poster
  • / A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).

A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).

Abstract Poster

Authors

null

Carmel Maree Jacobs

The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

Carmel Maree Jacobs, Iryna Kuchuk, Stephanie Smith, Sasha Mazzarello, Lisa Vandermeer, Nathan Bouganim, Susan Dent, Stan Z. Gertler, Shailendra Verma, Vince Young, Xinni Song, Demetrios Simos, George Dranitsaris, David Cella, Mark Clemons

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Palliative and Supportive Care in Oncology Symposium

Session Type

Poster Session

Session Title

General Poster Session A: End-of-Life Care, <span>Patient-Reported Outcomes</span>, and Survivorship

Track

Survivorship,Patient-Reported Outcomes: Mechanisms of Symptoms and Treatment Toxicities,Early Integration of Palliative Care in Cancer Care,Psycho-oncology,End-of-Life Care

Sub Track

Patient-Reported Outcomes: Mechanisms of Symptoms and Treatment Toxicities

Clinical Trial Registration Number

NCT01907880

Citation

J Clin Oncol 32, 2014 (suppl 31; abstr 155)

DOI

10.1200/jco.2014.32.31_suppl.155

Abstract #

155

Poster Bd #

D6

Abstract Disclosures

Similar Posters

First Author: Robert Edward Coleman

First Author: Lois Lamerato

First Author: A. Barnadas

First Author: Oth Tran